AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04733846 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: Collection of clinical and paraclinical data during preoperative consultation Collection of clinical and paraclinical data during post-operative consultations Tele-consultation to determine if criteria for good healing / adherence, treatment tolerance / response to questions Remote follow-up 6 and 12 months after the trauma
Study NCT04148599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine infusion
Description: a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.
Study NCT04148599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine infusion
Description: a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.
Study NCT04148599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
Study NCT02252692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: oral administration
Study NCT02252692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: oral administration
Study NCT03141372 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Void Trial using Foley catheter
Description: A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
Study NCT00261326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 80 mg once daily
Study NCT00261326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: calcium tablets once daily
Study NCT00814905 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ampicillin gentamicin clindamycin
Description: one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
Study NCT00814905 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ampicillin gentamicin clindamycin
Description: ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
Study NCT03963336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: Subcutaneous LMWH 1mg/kg/day for 2 weeks
Study NCT03963336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetazolamide
Description: Carbonic anhydrase inhibitor 1-2g/day for 6 months
Study NCT01850095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorspirenone/ethynil estradiol
Study NCT03525730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
Study NCT00946842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Study NCT00946842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Study NCT00002734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: lutetium Lu 177 monoclonal antibody CC49
Study NCT00002734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 monoclonal antibody CC49
Study NCT03525730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
Study NCT03021694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men
Study NCT03563846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP-G28
Description: RP-G28 is a purified galacto-oligosaccharide (GOS) product
Study NCT01135628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auxiliary Treatment
Description: Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
Study NCT01135628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hyperproteic and fiber-rich diet
Description: Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
Study NCT00946842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
Study NCT01135628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide tablets 400 mg, bid, orally for 6 months
Study NCT03383419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
Study NCT00344214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program
Description: This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
Study NCT00344214 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
Study NCT00831623 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: 3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
Study NCT00831623 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: As above
Study NCT00946842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitor
Description: Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
Study NCT00946842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
Study NCT00946842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicine
Description: Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine
Description: Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil (5FU)
Description: Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5FU)
Description: Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study NCT04389853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible ureteroscopy
Description: Retograde intrarenal surgery (RIRS) has gained much popularity especially when the role of SWL, in management of LPS, has been significantly diminished in the few last years5. RIRS is dependent mainly on flexible ureteroscopy (fURS). fURS increases the quality and performance of upper urinary tract exploration, allowing for the treatment of the majority of stones at all sites. Moreover, it is associated with no risk of renal parenchymal injuries and a very low risk of bleeding.
Study NCT04389853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-percutaneous nephrolithotomy
Description: PCNL has regained popularity thanks to the possibility of using reduced calibers and modern technology, which has reduced the complications without compromising the stone clearance, and more efficient intracorporeal lithotripter modalities. However, PCNL is still a challenging surgical technique and can be associated with significant complications that may compromise its efficacy. In the present time, we have available calibers ranging from 4.8 to 30 French. Many reports advocate that morbidity after PCNL may be reduced by recent modifications, such as mini-PCNL (miniperc). One meta-analysis of mini-PCNL and conventional PCNL demonstrated that mini-PCNL had a greater safety profile with similar stone free rates (SFRs).
Study NCT00799383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
Study NCT00799383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
Study NCT03385681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Educational Intervention
Description: The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
Study NCT03094182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
Study NCT03094182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study NCT00773695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study NCT00603291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg once daily (QD)
Description: Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
Study NCT00603291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice a day (BID)
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
Study NCT00603291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo tablet each morning and evening for a duration of 52 weeks.
Study NCT03643679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kwit smartphone app
Description: The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
Study NCT03078582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan (RA101495)
Description: 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Study NCT00953108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: 300 mg per day
Study NCT00953108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram 10 mg per day
Study NCT03166813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning
Description: The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
Study NCT03166813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placement of blood pressure cuff without inflation for 30 minutes.
Study NCT04054284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antidiabetic Herbal Tea
Description: Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
Study NCT04054284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbal Tea
Description: Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
Study NCT04544020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: NG feeding
Description: NG feeding
Study NCT02772952 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Intervention
Description: Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
Study NCT02772952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention
Description: Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
Study NCT01747122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound catheter
Description: Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
Study NCT01747122 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Study NCT04854252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
Study NCT03824990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement of management of neonatal jaundice
Description: During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
Study NCT02777918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipe provision
Description: 6 recipes will be provided every 2 weeks by post for 12 weeks
Study NCT02428179 — intervention group
Intervention type: PROCEDURE
Intervention: StOP? - Control group
Description: Control group - Surgical procedure without Study Intervention
Study NCT01680250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
Study NCT03950622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
Study NCT03950622 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
Study NCT02304055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
Study NCT02304055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
Study NCT01854229 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometra Programmable Intrathecal Infusion Pump
Description: There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
Study NCT03977935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the second-generation MCCG
Description: Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
Study NCT01587053 — intervention group
Intervention type: OTHER
Intervention: therapeutic education program
Study NCT03241017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Immunotherapy with Durvalumab after ASCT
Study NCT01224015 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
Study NCT01224015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.